BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 24642505)

  • 1. Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy.
    Cao L; Hu WG; Kirova YM; Yang ZZ; Cai G; Yu XL; Ma JL; Guo XM; Shao ZM; Chen JY
    Cancer Radiother; 2014 Mar; 18(2):119-24. PubMed ID: 24642505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab.
    Cao L; Cai G; Chang C; Yang ZZ; Feng Y; Yu XL; Ma JL; Wu J; Guo XM; Chen JY
    Oncotarget; 2016 Jan; 7(1):1042-54. PubMed ID: 26460956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab.
    Cao L; Cai G; Chang C; Miao AY; Yu XL; Yang ZZ; Ma JL; Zhang Q; Wu J; Guo XM; Chen JY
    Oncologist; 2015 Jun; 20(6):605-14. PubMed ID: 25933931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study.
    Shaffer R; Tyldesley S; Rolles M; Chia S; Mohamed I
    Radiother Oncol; 2009 Jan; 90(1):122-6. PubMed ID: 18976826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy].
    Jacob J; Belin L; Gobillion A; Daveau-Bergerault C; Dendale R; Beuzeboc P; Campana F; Bollet MA; Fourquet A; Kirova YM
    Cancer Radiother; 2013 Jun; 17(3):183-90. PubMed ID: 23499212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab-related cardiac events in the treatment of early breast cancer.
    Fried G; Regev T; Moskovitz M
    Breast Cancer Res Treat; 2013 Nov; 142(1):1-7. PubMed ID: 24154507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).
    de Azambuja E; Procter MJ; van Veldhuisen DJ; Agbor-Tarh D; Metzger-Filho O; Steinseifer J; Untch M; Smith IE; Gianni L; Baselga J; Jackisch C; Cameron DA; Bell R; Leyland-Jones B; Dowsett M; Gelber RD; Piccart-Gebhart MJ; Suter TM
    J Clin Oncol; 2014 Jul; 32(20):2159-65. PubMed ID: 24912899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer.
    Tarantini L; Cioffi G; Gori S; Tuccia F; Boccardi L; Bovelli D; Lestuzzi C; Maurea N; Oliva S; Russo G; Faggiano P;
    J Card Fail; 2012 Feb; 18(2):113-9. PubMed ID: 22300778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study.
    Caussa L; Kirova YM; Gault N; Pierga JY; Savignoni A; Campana F; Dendale R; Fourquet A; Bollet MA
    Eur J Cancer; 2011 Jan; 47(1):65-73. PubMed ID: 20843680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
    Guarneri V; Lenihan DJ; Valero V; Durand JB; Broglio K; Hess KR; Michaud LB; Gonzalez-Angulo AM; Hortobagyi GN; Esteva FJ
    J Clin Oncol; 2006 Sep; 24(25):4107-15. PubMed ID: 16908934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Concurrent radiation therapy and dual HER2 blockade in breast cancer: Assessment of toxicity].
    Ben Dhia S; Loap P; Loirat D; Vincent-Salomon A; Cao K; Escalup L; Fourquet A; Kirova Y
    Cancer Radiother; 2021 Jul; 25(5):424-431. PubMed ID: 33771453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity.
    Ajgal Z; de Percin S; Diéras V; Pierga JY; Campana F; Fourquet A; Kirova YM
    Cancer Radiother; 2017 Apr; 21(2):114-118. PubMed ID: 28347625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.
    Farolfi A; Melegari E; Aquilina M; Scarpi E; Ibrahim T; Maltoni R; Sarti S; Cecconetto L; Pietri E; Ferrario C; Fedeli A; Faedi M; Nanni O; Frassineti GL; Amadori D; Rocca A
    Heart; 2013 May; 99(9):634-9. PubMed ID: 23349345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No Acute Changes in LVEF Observed With Concurrent Trastuzumab and Breast Radiation With Low Heart Doses.
    Bian SX; Korah MP; Whitaker TR; Ji L; Groshen S; Chung E
    Clin Breast Cancer; 2017 Nov; 17(7):510-515. PubMed ID: 28412326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
    Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
    Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac Function After Multimodal Breast Cancer Therapy Assessed With Functional Magnetic Resonance Imaging and Echocardiography Imaging.
    Heggemann F; Grotz H; Welzel G; Dösch C; Hansmann J; Kraus-Tiefenbacher U; Attenberger U; Schönberg SO; Borggrefe M; Wenz F; Papavassiliu T; Lohr F
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):836-44. PubMed ID: 26530752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
    Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
    Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of adjuvant trastuzumab-associated cardiac toxicity in korean patients with breast cancer: a single-center analysis.
    Cha C; Ahn SG; Lee HM; Lee HW; Lee SA; Jeong J
    Oncology; 2013; 85(4):228-34. PubMed ID: 24081024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.
    Lamot C; Rottey S; De Backer T; Van Bortel L; Robays H; Van Belle S; Denys H; Cocquyt V
    Acta Clin Belg; 2010; 65(5):300-4. PubMed ID: 21128555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Primary safety analysis of trastuzumab after adjuvant chemotherapy in 30 Chinese Her2-positive early breast cancer patients].
    Zhou NN; Teng XY; Liu DG; Xu R; Guan ZZ
    Ai Zheng; 2008 Dec; 27(12):1307-9. PubMed ID: 19079999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.